HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Kubitza, D. Articles by Zuehlsdorf, M. Search for Related Content PubMed PubMed Citation Articles by Kubitza, D. Articles by Zuehlsdorf, M. Social Bookmarking                   What's this?

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin

From Clinical Pharmacology (Dr Kubitza, Dr Mueck, Dr Zuehlsdorf) and the Department of Biometry, Pharmacometry (Dr Becka), Bayer HealthCare AG, Wuppertal, Germany.

Rivaroxaban (BAY 59-7939) is an oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of thromboembolic disorders. This was a randomized, 2-way crossover study in healthy male subjects, with an aspirin run-in period, to examine whether aspirin influences the safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban. All treatments were well tolerated; drug-related adverse events were mild and transient. Aspirin did not alter the effects of rivaroxaban on Factor Xa activity or clotting tests. Platelet aggregation and bleeding time were not affected by rivaroxaban, and rivaroxaban did not influence the effects of aspirin on these parameters to a clinically relevant extent. Aspirin did not affect the pharmacokinetics of rivaroxaban, including the fraction unbound. This study suggests that there is no clinically relevant interaction between rivaroxaban and aspirin and that the 2 drugs could be administered concomitantly at the doses used in this study.

Key Words: Factor Xa inhibitors • aspirin • oral anticoagulants • rivaroxaban • BAY 59-7939

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. P. Gulseth, J. Michaud, and E. A. Nutescu Rivaroxaban: An oral direct inhibitor of factor Xa Am. J. Health Syst. Pharm., August 15, 2008; 65(16): 1520 - 1529. [Abstract] [Full Text] [PDF]

				A. G.G. Turpie New oral anticoagulants in atrial fibrillation Eur. Heart J., January 2, 2008; 29(2): 155 - 165. [Abstract] [Full Text] [PDF]

				A. G.G. Turpie Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1238 - 1247. [Abstract] [Full Text] [PDF]

				D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects J. Clin. Pharmacol., February 1, 2007; 47(2): 218 - 226. [Abstract] [Full Text] [PDF]